229 related articles for article (PubMed ID: 31092386)
1. Challenges in the diagnosis and treatment of secondary acute myeloid leukemia.
Ossenkoppele G; Montesinos P
Crit Rev Oncol Hematol; 2019 Jun; 138():6-13. PubMed ID: 31092386
[TBL] [Abstract][Full Text] [Related]
2. Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML.
Chen EC; Fathi AT; Brunner AM
Onco Targets Ther; 2018; 11():3425-3434. PubMed ID: 29928134
[TBL] [Abstract][Full Text] [Related]
3. Characteristics and Outcomes of Secondary Acute Myeloid Leukemia and Acute Myeloid Leukemia With Myelodysplasia-Related Changes: Multicenter Study From the Thai Acute Leukemia Study Group.
Chanswangphuwana C; Polprasert C; Owattanapanich W; Kungwankiattichai S; Tantiworawit A; Rattanathammethee T; Limvorapitak W; Saengboon S; Niparuck P; Puavilai T; Julamanee J; Saelue P; Wanitpongpun C; Nakhakes C; Prayongratana K; Sriswasdi C
Clin Lymphoma Myeloma Leuk; 2022 Dec; 22(12):e1075-e1083. PubMed ID: 36117042
[TBL] [Abstract][Full Text] [Related]
4. Outcome of patients aged 60-75 years with newly diagnosed secondary acute myeloid leukemia: A single-institution experience.
Bertoli S; Tavitian S; Bories P; Luquet I; Delabesse E; Comont T; Sarry A; Huguet F; Bérard E; Récher C
Cancer Med; 2019 Jul; 8(8):3846-3854. PubMed ID: 31173485
[TBL] [Abstract][Full Text] [Related]
5. Secondary Acute Myeloid Leukemia (sAML): Similarly Dismal Outcomes of AML After an Antecedent Hematologic Disorder and Therapy Related AML.
Lalayanni C; Gavriilaki E; Athanasiadou A; Iskas M; Papathanasiou M; Marvaki A; Mpesikli S; Papaioannou G; Mallouri D; Batsis I; Papalexandri A; Sakellari I; Anagnostopoulos A
Clin Lymphoma Myeloma Leuk; 2022 Apr; 22(4):e233-e240. PubMed ID: 34756570
[TBL] [Abstract][Full Text] [Related]
6. CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia.
Lancet JE; Uy GL; Cortes JE; Newell LF; Lin TL; Ritchie EK; Stuart RK; Strickland SA; Hogge D; Solomon SR; Stone RM; Bixby DL; Kolitz JE; Schiller GJ; Wieduwilt MJ; Ryan DH; Hoering A; Banerjee K; Chiarella M; Louie AC; Medeiros BC
J Clin Oncol; 2018 Sep; 36(26):2684-2692. PubMed ID: 30024784
[TBL] [Abstract][Full Text] [Related]
7. Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study.
Granfeldt Østgård LS; Medeiros BC; Sengeløv H; Nørgaard M; Andersen MK; Dufva IH; Friis LS; Kjeldsen E; Marcher CW; Preiss B; Severinsen M; Nørgaard JM
J Clin Oncol; 2015 Nov; 33(31):3641-9. PubMed ID: 26304885
[TBL] [Abstract][Full Text] [Related]
8. CPX-351 daunorubicin-cytarabine liposome: a novel formulation to treat patients with newly diagnosed secondary acute myeloid leukemia.
Cafaro A; Giannini MB; Silimbani P; Cangini D; Masini C; Ghelli Luserna Di Rorà A; Simonetti G; Martinelli G; Cerchione C
Minerva Med; 2020 Oct; 111(5):455-466. PubMed ID: 32955826
[TBL] [Abstract][Full Text] [Related]
9. Quality-adjusted Time Without Symptoms of disease or Toxicity (Q-TWiST) analysis of CPX-351 versus 7 + 3 in older adults with newly diagnosed high-risk/secondary AML.
Cortes JE; Lin TL; Uy GL; Ryan RJ; Faderl S; Lancet JE
J Hematol Oncol; 2021 Jul; 14(1):110. PubMed ID: 34256819
[TBL] [Abstract][Full Text] [Related]
10. CPX-351 (vyxeos) in AML.
Alfayez M; Kantarjian H; Kadia T; Ravandi-Kashani F; Daver N
Leuk Lymphoma; 2020 Feb; 61(2):288-297. PubMed ID: 31547736
[TBL] [Abstract][Full Text] [Related]
11. Elderly Patients (Age 70 Years or Older) With Secondary Acute Myeloid Leukemia or Acute Myeloid Leukemia Developed Concurrently to Another Malignant Disease.
Collinge E; Loron S; Larcher MV; Elhamri M; Heiblig M; Deloire A; Ducastelle S; Labussière H; Barraco F; Wattel E; Salles G; Paubelle E; Thomas X
Clin Lymphoma Myeloma Leuk; 2018 May; 18(5):e211-e218. PubMed ID: 29572159
[TBL] [Abstract][Full Text] [Related]
12. CPX-351: changing the landscape of treatment for patients with secondary acute myeloid leukemia.
Talati C; Lancet JE
Future Oncol; 2018 May; 14(12):1147-1154. PubMed ID: 29378418
[TBL] [Abstract][Full Text] [Related]
13. Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study.
Martínez-Cuadrón D; Megías-Vericat JE; Serrano J; Martínez-Sánchez P; Rodríguez-Arbolí E; Gil C; Aguiar E; Bergua J; López-Lorenzo JL; Bernal T; Espadana A; Colorado M; Rodríguez-Medina C; López-Pavía M; Tormo M; Algarra L; Amigo ML; Sayas MJ; Labrador J; Rodríguez-Gutiérrez JI; Benavente C; Costilla-Barriga L; García-Boyero R; Lavilla-Rubira E; Vives S; Herrera P; García-Belmonte D; Herráez MM; Vasconcelos Esteves G; Gómez-Roncero MI; Cabello A; Bautista G; Balerdi A; Mariz J; Boluda B; Sanz MÁ; Montesinos P
Blood Adv; 2022 Feb; 6(4):1278-1295. PubMed ID: 34794172
[TBL] [Abstract][Full Text] [Related]
14. Daunorubicin and cytarabine for certain types of poor-prognosis acute myeloid leukemia: a systematic literature review.
Megías-Vericat JE; Martínez-Cuadrón D; Sanz MÁ; Poveda JL; Montesinos P
Expert Rev Clin Pharmacol; 2019 Mar; 12(3):197-218. PubMed ID: 30672340
[TBL] [Abstract][Full Text] [Related]
15. Liposomal encapsulated cytarabine and daunorubicin (CPX-351) for older patients with acute myeloid leukemia.
Asghari H; Lancet J
Leuk Lymphoma; 2020 Jun; 61(6):1305-1312. PubMed ID: 32037927
[TBL] [Abstract][Full Text] [Related]
16. Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens.
Seymour JF; Döhner H; Butrym A; Wierzbowska A; Selleslag D; Jang JH; Kumar R; Cavenagh J; Schuh AC; Candoni A; Récher C; Sandhu I; Del Castillo TB; Al-Ali HK; Falantes J; Stone RM; Minden MD; Weaver J; Songer S; Beach CL; Dombret H
BMC Cancer; 2017 Dec; 17(1):852. PubMed ID: 29241450
[TBL] [Abstract][Full Text] [Related]
17. Secondary AML Emerging After Therapy with Hypomethylating Agents: Outcomes, Prognostic Factors, and Treatment Options.
Richardson DR; Green SD; Foster MC; Zeidner JF
Curr Hematol Malig Rep; 2021 Feb; 16(1):97-111. PubMed ID: 33609248
[TBL] [Abstract][Full Text] [Related]
18. Diagnosis and treatment of therapy-related acute myeloid leukemia.
Strickland SA; Vey N
Crit Rev Oncol Hematol; 2022 Mar; 171():103607. PubMed ID: 35101585
[TBL] [Abstract][Full Text] [Related]
19. Secondary acute myeloid leukemia - a single center experience.
Szotkowski T; Rohon P; Zapletalova L; Sicova K; Hubacek J; Indrak K
Neoplasma; 2010; 57(2):170-8. PubMed ID: 20099982
[TBL] [Abstract][Full Text] [Related]
20. The FOSSIL Study: FLAG or standard 7+3 induction therapy in secondary acute myeloid leukemia.
Vulaj V; Perissinotti AJ; Uebel JR; Nachar VR; Scappaticci GB; Crouch A; Bixby DL; Burke PW; Maillard I; Talpaz M; Marini BL
Leuk Res; 2018 Jul; 70():91-96. PubMed ID: 29908418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
